JOHNSON & JOHNSON |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 149.3 USD | -0.43% |
|
+2.14% | -4.77% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 88.37B | Sales 2025 * | 90.78B | Capitalization | 359B |
|---|---|---|---|---|---|
| Net income 2024 * | 22.04B | Net income 2025 * | 22.98B | EV / Sales 2024 * | 3.99 x |
| Net cash position 2024 * | 7B | Net cash position 2025 * | 21.07B | EV / Sales 2025 * | 3.73 x |
| P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
15.7
x | Employees | 131,900 |
| Yield 2024 * |
3.23% | Yield 2025 * |
3.37% | Free-Float | 77.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Johnson & Johnson
More recommendations
More press releases
More news
| 1 day | -0.43% | ||
| 1 week | +2.14% | ||
| Current month | +3.24% | ||
| 1 month | -2.05% | ||
| 3 months | -4.19% | ||
| 6 months | -1.37% | ||
| Current year | -4.77% |
1 week
144.53
152.33
1 month
143.13153.04
Current year
143.13163.58
1 year
143.13175.97
3 years
143.13186.69
5 years
109.16186.69
10 years
81.79186.69
| Managers | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 88-12-31 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 97-12-31 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 19-11-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 19-04-24 |
D. Davis
BRD | Director/Board Member | 72 | 14-06-18 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 09-10-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.01% | 215 M€ | +10.80% | - | |
| 12.91% | 18 M€ | +3.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 149.3 | -0.43% | 6,532,718 |
| 24-05-02 | 149.9 | -0.83% | 8,459,796 |
| 24-05-01 | 151.2 | +4.56% | 14,473,711 |
| 24-04-30 | 144.6 | -1.52% | 8,817,719 |
| 24-04-29 | 146.8 | +0.47% | 6,461,588 |
Delayed Quote Nyse, May 03, 2024 at 04:00 pm EDT
More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
149.3
USD
Average target price
173.3
USD
Spread / Average Target
+16.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.77% | 359B | |
| +26.08% | 662B | |
| +22.59% | 546B | |
| +16.97% | 323B | |
| +5.69% | 289B | |
| +13.68% | 234B | |
| +4.32% | 198B | |
| -10.80% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- JNJ Stock